NASDAQ:APVO - Aptevo Therapeutics Stock Price, Forecast & News

Aptevo Therapeutics trades on the NASDAQ under the ticker symbol "APVO."

Aptevo Therapeutics Inc (NASDAQ:APVO) posted its earnings results on Thursday, November, 7th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.01. The biotechnology company earned $9.01 million during the quarter, compared to analysts' expectations of $8.05 million. Aptevo Therapeutics had a negative net margin of 156.03% and a negative return on equity of 171.99%. View Aptevo Therapeutics' Earnings History.

Aptevo Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Aptevo Therapeutics.

2 equities research analysts have issued 1 year target prices for Aptevo Therapeutics' stock. Their forecasts range from $3.00 to $3.00. On average, they expect Aptevo Therapeutics' stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 527.4% from the stock's current price. View Analyst Price Targets for Aptevo Therapeutics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptevo Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aptevo Therapeutics.

News coverage about APVO stock has trended negative this week, InfoTrie Sentiment reports. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Aptevo Therapeutics earned a media sentiment score of -2.0 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Aptevo Therapeutics.

Aptevo Therapeutics saw a decline in short interest in the month of January. As of January 31st, there was short interest totalling 1,500,000 shares, a decline of 10.7% from the January 15th total of 1,680,000 shares. Based on an average daily trading volume, of 366,700 shares, the days-to-cover ratio is presently 4.1 days. Currently, 3.7% of the shares of the stock are short sold. View Aptevo Therapeutics' Current Options Chain.

Some companies that are related to Aptevo Therapeutics include VERONA PHARMA P/S (VRNA), Oramed Pharmaceuticals (ORMP), Checkpoint Therapeutics (CKPT), CV Sciences (CVSI), AVEO Pharmaceuticals (AVEO), Catalyst Biosciences (CBIO), Neos Therapeutics (NEOS), Infinity Pharmaceuticals (INFI), Elite Pharmaceuticals (ELTP), Onconova Therapeutics (ONTX), Stealth BioTherapeutics (MITO), Eyenovia (EYEN), CTI BioPharma (CTIC), Oncolytics Biotech (ONCY) and Entasis Therapeutics (ETTX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptevo Therapeutics investors own include Zynerba Pharmaceuticals (ZYNE), AbbVie (ABBV), Advanced Micro Devices (AMD), AVEO Pharmaceuticals (AVEO), Corbus Pharmaceuticals (CRBP), NVIDIA (NVDA), Synergy Pharmaceuticals (SGYP), Alibaba Group (BABA), BIOLINERX LTD/S (BLRX) and Exelixis (EXEL).

Aptevo Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (5.26%), UBS Group AG (0.39%) and Bank of New York Mellon Corp (0.12%). Company insiders that own Aptevo Therapeutics stock include Barbara Lopez Kunz, Daniel Abdun-Nabi, Fuad El-Hibri, Grady Grant III, Marvin L White, Randy Joe Maddux and Zsolt Harsanyi. View Institutional Ownership Trends for Aptevo Therapeutics.

APVO stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp. View Insider Buying and Selling for Aptevo Therapeutics.

APVO stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and UBS Group AG. Company insiders that have bought Aptevo Therapeutics stock in the last two years include Barbara Lopez Kunz, Daniel Abdun-Nabi, Fuad El-Hibri, Grady Grant III, Marvin L White, Randy Joe Maddux and Zsolt Harsanyi. View Insider Buying and Selling for Aptevo Therapeutics.

Shares of APVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of APVO stock can currently be purchased for approximately $0.48.

Aptevo Therapeutics has a market capitalization of $21.65 million and generates $23.07 million in revenue each year. The biotechnology company earns $-53,690,000.00 in net income (profit) each year or ($2.39) on an earnings per share basis. Aptevo Therapeutics employs 118 workers across the globe.View Additional Information About Aptevo Therapeutics.

The official website for Aptevo Therapeutics is http://www.aptevotherapeutics.com/.

Aptevo Therapeutics' mailing address is 2401 4TH AVENUE SUITE 1050, SEATTLE WA, 98121. The biotechnology company can be reached via phone at 206-838-0500 or via email at [email protected]